127 related articles for article (PubMed ID: 38363830)
1. STING licensing of type I dendritic cells potentiates antitumor immunity.
Wang J; Li S; Wang M; Wang X; Chen S; Sun Z; Ren X; Huang G; Sumer BD; Yan N; Fu YX; Gao J
Sci Immunol; 2024 Feb; 9(92):eadj3945. PubMed ID: 38363830
[TBL] [Abstract][Full Text] [Related]
2. STING Licensing of Type I Dendritic Cells Potentiates Antitumor Immunity.
Wang J; Li S; Wang M; Wang X; Chen S; Sun Z; Ren X; Huang G; Sumer BD; Yan N; Fu YX; Gao J
bioRxiv; 2024 Jan; ():. PubMed ID: 38260493
[TBL] [Abstract][Full Text] [Related]
3. The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake.
de Mingo Pulido Á; Hänggi K; Celias DP; Gardner A; Li J; Batista-Bittencourt B; Mohamed E; Trillo-Tinoco J; Osunmakinde O; Peña R; Onimus A; Kaisho T; Kaufmann J; McEachern K; Soliman H; Luca VC; Rodriguez PC; Yu X; Ruffell B
Immunity; 2021 Jun; 54(6):1154-1167.e7. PubMed ID: 33979578
[TBL] [Abstract][Full Text] [Related]
4. Batf3-dependent orchestration of the robust Th1 responses and fungal control during cryptococcal infection, the role of cDC1.
Xu J; Hissong R; Bareis R; Creech A; Goughenour KD; Freeman CM; Olszewski MA
mBio; 2024 Mar; 15(3):e0285323. PubMed ID: 38349130
[TBL] [Abstract][Full Text] [Related]
5. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants.
Conde E; Vercher E; Soria-Castellano M; Suarez-Olmos J; Mancheño U; Elizalde E; Rodriguez ML; Glez-Vaz J; Casares N; Rodríguez-García E; Hommel M; González-Aseguinolaza G; Uranga-Murillo I; Pardo J; Alkorta G; Melero I; Lasarte J; Hervas-Stubbs S
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34810235
[TBL] [Abstract][Full Text] [Related]
6. Rocaglamide promotes the infiltration and antitumor immunity of NK cells by activating cGAS-STING signaling in non-small cell lung cancer.
Yan X; Yao C; Fang C; Han M; Gong C; Hu D; Shen W; Wang L; Li S; Zhu S
Int J Biol Sci; 2022; 18(2):585-598. PubMed ID: 35002511
[No Abstract] [Full Text] [Related]
7.
Theisen DJ; Ferris ST; Briseño CG; Kretzer N; Iwata A; Murphy KM; Murphy TL
Cancer Immunol Res; 2019 Jan; 7(1):29-39. PubMed ID: 30482745
[TBL] [Abstract][Full Text] [Related]
8. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.
Cueto FJ; Del Fresno C; Brandi P; Combes AJ; Hernández-García E; Sánchez-Paulete AR; Enamorado M; Bromley CP; Gomez MJ; Conde-Garrosa R; Mañes S; Zelenay S; Melero I; Iborra S; Krummel MF; Sancho D
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980589
[TBL] [Abstract][Full Text] [Related]
9. T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer.
Ni H; Zhang H; Li L; Huang H; Guo H; Zhang L; Li C; Xu JX; Nie CP; Li K; Zhang X; Xia X; Li J
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36126994
[TBL] [Abstract][Full Text] [Related]
10. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
[TBL] [Abstract][Full Text] [Related]
11. STING Signaling in Cancer Cells: Important or Not?
Sokolowska O; Nowis D
Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):125-132. PubMed ID: 28748479
[TBL] [Abstract][Full Text] [Related]
12. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
13. Engineering and Delivery of cGAS-STING Immunomodulators for the Immunotherapy of Cancer and Autoimmune Diseases.
Zhou S; Cheng F; Zhang Y; Su T; Zhu G
Acc Chem Res; 2023 Nov; 56(21):2933-2943. PubMed ID: 37802125
[TBL] [Abstract][Full Text] [Related]
14. Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy.
Teijeira A; Garasa S; Luri-Rey C; de Andrea C; Gato M; Molina C; Kaisho T; Cirella A; Azpilikueta A; Wculek SK; Egea J; Olivera I; Rodriguez I; Rouzaut A; Verkhusha V; Valencia K; Sancho D; Berraondo P; Melero I
Cancer Res; 2022 Dec; 82(23):4373-4385. PubMed ID: 36130020
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant
Oba T; Kajihara R; Yokoi T; Repasky EA; Ito F
Cancer Res; 2021 Dec; 81(24):6183-6195. PubMed ID: 34666993
[TBL] [Abstract][Full Text] [Related]
16. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.
Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988
[TBL] [Abstract][Full Text] [Related]
17. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
Deng L; Liang H; Xu M; Yang X; Burnette B; Arina A; Li XD; Mauceri H; Beckett M; Darga T; Huang X; Gajewski TF; Chen ZJ; Fu YX; Weichselbaum RR
Immunity; 2014 Nov; 41(5):843-52. PubMed ID: 25517616
[TBL] [Abstract][Full Text] [Related]
18. Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1
Tsuchiya N; Zhang R; Iwama T; Ueda N; Liu T; Tatsumi M; Sasaki Y; Shimoda R; Osako Y; Sawada Y; Kubo Y; Miyashita A; Fukushima S; Cheng Z; Nakaki R; Takubo K; Okada S; Kaneko S; Ihn H; Kaisho T; Nishimura Y; Senju S; Endo I; Nakatsura T; Uemura Y
Cell Rep; 2019 Oct; 29(1):162-175.e9. PubMed ID: 31577946
[TBL] [Abstract][Full Text] [Related]
19. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
20. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103
Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
